Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 TAR-210 versus intravesical chemotherapy in FGFR-altered high-risk non-muscle-invasive bladder cancer after BCG
2024-519493-39-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of erdafitinib in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Disease-free survival. Planned start Dec 2025; status: authorised.
02
Drugs
erdafitinib
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2024-519493-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519493-39-00.